Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 1.00 |
| ▸ | OGFRL1 | Q5TC84 | 8/20 | 1.00 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CFTR | P13569 | 3/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304962 | 0.89 | OPRM1 (0.80) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL3564418 | 0.87 | OPRM1 (0.77) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL733564 | 0.83 | OPRM1 (0.71) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL3563012 | 0.81 | OPRM1 (0.67) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL3408966 | 0.81 | OPRM1 (0.67) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL517133 | 0.80 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1LMNAOPRK1 | |
| SCHEMBL10038853 | 0.80 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1LMNAOPRK1 | |
| SCHEMBL3572216 | 0.80 | OPRM1 (0.66) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL1303569 | 0.79 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1LMNAOPRK1 | |
| SCHEMBL998281 | 0.77 | LMNA (0.94) | OPRM1OGFRL1OPRL1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319440-A1 | Process for Preparing Spirocyclic Cyclohexane Compounds, Compositions Containing Such Compounds and Method of Using Such Compounds | GRUENENTHAL GMBH (DE) | 2011-12-29 | — | — | US | claimed |
| US-20110053970-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | GRUENENTHAL GMBH (DE) | 2011-03-03 | — | — | US | claimed |
| US-20090156626-A1 | Process for Preparing Spirocyclic Cyclohexane Compounds and Methods of Using Such Compounds | GRENENTHAL GMBH (DE) | 2009-06-18 | — | — | US | claimed |
| US-7547707-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2009-06-16 | — | — | US | claimed |
| US-20080221141-A1 | 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor | GRUENENTHAL GMBH (DE) | 2008-09-11 | — | — | US | claimed |
| US-9862719-B2 | Process or preparing spirocyclic cyclohexane compounds, compositions containing such compounds and method of using such compounds | GRUENENTHAL GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| US-9862719-B2 | Process or preparing spirocyclic cyclohexane compounds, compositions containing such compounds and method of using such compounds | GRUENENTHAL GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| US-20160271107-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | GRUENENTHAL GMBH (DE) | 2016-09-22 | — | — | US | disclosed |
| US-20160271107-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | GRUENENTHAL GMBH (DE) | 2016-09-22 | — | — | US | disclosed |
| US-20160271107-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | GRUENENTHAL GMBH (DE) | 2016-09-22 | — | — | US | disclosed |
| US-20150322080-A1 | Process for Preparing Spirocyclic Cyclohexane Compounds, Compositions Containing Such Compounds and Method of Using Such Compounds | ADNEURIS THERAPEUTICS, INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150322080-A1 | Process for Preparing Spirocyclic Cyclohexane Compounds, Compositions Containing Such Compounds and Method of Using Such Compounds | ADNEURIS THERAPEUTICS, INC. | 2015-11-12 | — | — | US | disclosed |
| US-20090156626-A1 | Process for Preparing Spirocyclic Cyclohexane Compounds and Methods of Using Such Compounds | GRENENTHAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-7547707-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2009-06-16 | — | — | US | disclosed |
| US-7547707-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2009-06-16 | — | — | US | disclosed |
| US-7547707-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2009-06-16 | — | — | US | disclosed |
| EP-2062898-A2 | Spirocyclic cyclohexane derivatives | Grünenthal GmbH (DE) | 2009-05-27 | — | — | EP | disclosed |
| US-20080221141-A1 | 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor | GRUENENTHAL GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221141-A1 | 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor | GRUENENTHAL GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221141-A1 | 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor | GRUENENTHAL GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221141-A1 | 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OGFRL1 34/4885OPRL1 4/4885 |
| US-20110319440-A1 | Process for Preparing Spirocyclic Cyclohexane Compounds, Compositions Containing Such Compounds and Method of Using Such Compounds | PKD1, VKORC1, PKD2 | OPRM1 2030/4885OGFRL1 1903/4885OPRL1 1031/4885 |
| US-20110053970-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | TACR2, OPRK1, OPRD1 | OPRM1 8/4885OGFRL1 307/4885OPRL1 12/4885 |
| US-20150322080-A1 | Process for Preparing Spirocyclic Cyclohexane Compounds, Compositions Containing Such Compounds and Method of Using Such Compounds | PKD1, VKORC1, PKD2 | OPRM1 2030/4885OGFRL1 1903/4885OPRL1 1031/4885 |
| US-20160271107-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | TACR2, OPRK1, OPRD1 | OPRM1 8/4885OGFRL1 307/4885OPRL1 12/4885 |
| US-20090156626-A1 | Process for Preparing Spirocyclic Cyclohexane Compounds and Methods of Using Such Compounds | PKD1, VKORC1, PKD2 | OPRM1 1881/4885OGFRL1 1971/4885OPRL1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.